Clinical trials
Terminated Phase 3 trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
474 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 5 |
| 2002 | 3 |
| 2003 | 6 |
| 2004 | 7 |
| 2005 | 20 |
| 2006 | 17 |
| 2007 | 14 |
| 2008 | 27 |
| 2009 | 23 |
| 2010 | 21 |
| 2011 | 29 |
| 2012 | 17 |
| 2013 | 19 |
| 2014 | 25 |
| 2015 | 30 |
| 2016 | 24 |
| 2017 | 24 |
| 2018 | 35 |
| 2019 | 25 |
| 2020 | 27 |
| 2021 | 35 |
| 2022 | 26 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 474 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 27 |
| Hoffmann-La Roche | 25 |
| Pfizer | 23 |
| GlaxoSmithKline | 19 |
| Sanofi | 19 |
| Amgen | 16 |
| European Organisation for Research and Treatment of Cancer - EORTC | 13 |
| Gilead Sciences | 13 |
| Biogen | 11 |
| Janssen Research & Development, LLC | 11 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 20 |
| Alzheimer Disease | 18 |
| Crohn Disease | 17 |
| Neoplasm Metastasis | 15 |
| Neoplasms | 15 |
| Breast Neoplasms | 13 |
| Prostatic Neoplasms | 11 |
| Cardiovascular Diseases | 9 |
| Ovarian Neoplasms | 9 |
| Pulmonary Arterial Hypertension | 9 |
Trials
Showing 1 to 25 of 474. Each trial links to its page on Pharma Observatory.
374 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.